Sanara MedTech stock: FTC extends merger review. Sanara MedTech stock faces a 30-day wait

Published on 10/28/2026 at 06:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The October 15, 2026 FTC request added 30 days to the merger wait. Sanara MedTech stock posted USD 28.14 million revenue versus USD 28.95 million expected.

Merger timeline and earnings

The October 15, 2026 FTC request added 30 days to Sanara's merger review.
Second-quarter revenue was USD 28.14 million versus USD 28.95 million expected.
MarketBeat lists November 9, 2026 for the conference call and November 11, 2026 for earnings.

SMTI, US79957L1008, Illustration mit AI erstellt.

Sanara MedTech Inc. (ISIN US79957L1008) faces a longer regulatory path for its planned merger with MiMedx after the Federal Trade Commission requested additional information on October 15, 2026. The request extends the Hart-Scott-Rodino waiting period to 30 days after substantial compliance, according to the company's filing with the SEC.

What does the 30-day wait mean?

The review changes the timing of a transaction that Sanara and MiMedx had targeted for completion by the end of 2026. Completion remains subject to the waiting period and other closing conditions, so the regulatory process is now the central variable for the deal.

Sanara shareholders approved the merger on September 30, 2026, with 6,372,989 votes in favor, 1,944 against and 36,494 abstentions. Under the July 29, 2026 agreement, each Sanara share is to receive USD 33.00 in cash and 0.4735 MiMedx shares, with consideration valued at USD 35.00 per share, according to TokenPost.

Revenue missed expectations

Sanara reported second-quarter 2026 revenue of USD 28.14 million, below the USD 28.95 million consensus estimate, while adjusted loss reached USD 0.05 per share versus an expected USD 0.02 loss. MarketBeat said five firms had a consensus Reduce rating, with an average 12-month target of USD 35.00.

Three events shape the timeline

On July 29, 2026, Sanara and MiMedx agreed the USD 35.00-per-share transaction; on September 30, 2026, shareholders approved it with 6,372,989 votes in favor. On October 15, 2026, the FTC issued the Second Request, extending the waiting period by 30 days after substantial compliance.

Upcoming reporting dates

MarketBeat lists November 9, 2026 at 4:00 p.m. ET for the conference call and November 11, 2026 for the third-quarter earnings announcement, with the dates described as estimates.

Regulatory timing remains decisive

For Sanara investors, the merger timetable and the next earnings update now provide the clearest checkpoints. The latest market capitalization was USD 304.5 million on October 21, 2026, while the 52-week range stood at USD 16.05 to USD 35.52.